Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Optimizing Breathlessness Management in Amyotrophic Lateral Sclerosis: Insights from a Comprehensive Systematic Review

View through CrossRef
Abstract Background: Breathlessness is a prevalent symptom affecting the quality of life (QOL) of Amyotrophic Lateral Sclerosis (ALS) patients. This systematic review explored the interventions for controlling breathlessness in ALS patients, emphasizing palliative care (PALC), non-invasive ventilation (NIV), opioids, and non-pharmacological strategies. Methods: A comprehensive search of PubMed, Cochrane Library, and Web of Science databases was conducted. Eligibility criteria encompassed adults with ALS or motor neuron disease experiencing breathlessness. Outcomes included QOL and symptom control. Study designs comprised qualitative studies, cohort studies, and randomized controlled trials. Results: Eight studies were included, most exhibiting low bias risk, comprising one randomized controlled trial, three cohort studies, two comparative retrospective studies, and two qualitative studies (interviews). Most studies originated from Europe, with one from the United States of America. The participants totaled 3423, with ALS patients constituting 95.6%. PALC consultations significantly improved symptom assessment, advanced care planning, and discussions about goals of care. NIV demonstrated efficacy in managing breathlessness, with considerations for device limitations. Opioids were effective, though predominantly studied in non-ALS patients. Non-pharmacological strategies varied in efficacy among patients. Conclusion: The findings underscore the need for individualized approaches in managing breathlessness in ALS. PALC, NIV, opioids, and non-pharmacological strategies play crucial roles, each with their unique considerations. Further research, especially ALS-specific self-management studies, is warranted.
Title: Optimizing Breathlessness Management in Amyotrophic Lateral Sclerosis: Insights from a Comprehensive Systematic Review
Description:
Abstract Background: Breathlessness is a prevalent symptom affecting the quality of life (QOL) of Amyotrophic Lateral Sclerosis (ALS) patients.
This systematic review explored the interventions for controlling breathlessness in ALS patients, emphasizing palliative care (PALC), non-invasive ventilation (NIV), opioids, and non-pharmacological strategies.
Methods: A comprehensive search of PubMed, Cochrane Library, and Web of Science databases was conducted.
Eligibility criteria encompassed adults with ALS or motor neuron disease experiencing breathlessness.
Outcomes included QOL and symptom control.
Study designs comprised qualitative studies, cohort studies, and randomized controlled trials.
Results: Eight studies were included, most exhibiting low bias risk, comprising one randomized controlled trial, three cohort studies, two comparative retrospective studies, and two qualitative studies (interviews).
Most studies originated from Europe, with one from the United States of America.
The participants totaled 3423, with ALS patients constituting 95.
6%.
PALC consultations significantly improved symptom assessment, advanced care planning, and discussions about goals of care.
NIV demonstrated efficacy in managing breathlessness, with considerations for device limitations.
Opioids were effective, though predominantly studied in non-ALS patients.
Non-pharmacological strategies varied in efficacy among patients.
Conclusion: The findings underscore the need for individualized approaches in managing breathlessness in ALS.
PALC, NIV, opioids, and non-pharmacological strategies play crucial roles, each with their unique considerations.
Further research, especially ALS-specific self-management studies, is warranted.

Related Results

Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical a...
Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Abstract Amyotrophic lateral sclerosis is a progressive neurodegenerative syndrome characterized by loss of motor neurons. Cognit...
Amyotrophic lateral sclerosis: Neural repair strategies based on multi-target synchronous interventions
Amyotrophic lateral sclerosis: Neural repair strategies based on multi-target synchronous interventions
Abstract Amyotrophic lateral sclerosis is a progressive and fatal neurodegenerative disease that targets motor neurons in the cerebral cortex, medulla oblongata, ...
Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration
Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration
Abstract TDP-43 is mislocalized from the nucleus and aggregates within the cytoplasm of affected neurons in cases of amyotrophic lateral sclerosis. TDP-43 pathology ...
Hydatid Cyst of The Orbit: A Systematic Review with Meta-Data
Hydatid Cyst of The Orbit: A Systematic Review with Meta-Data
Abstarct Introduction Orbital hydatid cysts (HCs) constitute less than 1% of all cases of hydatidosis, yet their occurrence is often linked to severe visual complications. This stu...
Urinary biomarkers for amyotrophic lateral sclerosis: candidates, opportunities and considerations
Urinary biomarkers for amyotrophic lateral sclerosis: candidates, opportunities and considerations
Abstract Amyotrophic lateral sclerosis is a relentless neurodegenerative disease that is mostly fatal within 3–5 years and is diagnosed on evidence of progressive up...
Amyotrophic Lateral Sclerosis and its Masks, a Comorbid Pathology with a Rapid Fatal Outcome: Case Report
Amyotrophic Lateral Sclerosis and its Masks, a Comorbid Pathology with a Rapid Fatal Outcome: Case Report
INTRODUCTION. Despite the fact that more than 150 years have passed since the first mention of amyotrophic lateral sclerosis (ALS), the issues of etiology, pathogenesis, diagnosis ...

Back to Top